ITA2151
ITA2151
ITA2151
from
$526.00
Price in reward points: 526
- Catalog: ITA2151
- Gene/Protein: ST14
- Product Description: Immunotag™ Matriptase Antibody
-
Description
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein Matriptase Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,IHC,IF/ICC,ELISA Recommended Dilution WB 1:1000 IHC 1:200, IF/ICC 1:100-1:500 Concentration 1 mg/ml Reactive Species Human,Mouse Host Species Rabbit Immunogen A synthesized peptide derived from human Matriptase Specificity Matriptase Antibody detects endogenous levels of total Matriptase Purification The antiserum was purified by peptide affinity chromatography. Form Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt Gene Name ST14 Accession No. Q9Y5Y6 Alternate Names Epithin; HAI; Matriptase; Membrane type serine protease 1; Membrane type serine protease; Membrane-type serine protease 1; MT SP1; MT-SP1; MTSP 1; MTSP1; Prostamin; PRSS 14; PRSS14; Serine protease 14; Serine protease TADG 15; Serine protease TADG-15; Serine protease TADG15; SNC 19; SNC19; ST 14; ST14; ST14_HUMAN; Suppression of tumorigenicity 14 (colon carcinoma matriptase epithin); Suppression of tumorigenicity 14 (colon carcinoma); Suppression of tumorigenicity 14; Suppressor of tumorigenicity 14 protein; Suppressor of tumorigenicity protein 14; TADG 15; TADG15; TMPRSS14; Tumor associated differentially expressed gene 15 protein; Tumor-associated differentially-expressed gene 15 protein; Description Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site. Involved in the terminal differentiation of keratinocytes through prostasin (PRSS8) activation and filaggrin (FLG) processing. Cell Pathway/ Category Primary Polyclonal Antibody Protein MW 95kDa Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet |
|
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | Matriptase |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC,IF/ICC,ELISA |
| Recommended Dilution | WB 1:1000 IHC 1:200, IF/ICC 1:100-1:500 |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Mouse |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human Matriptase |
| Specificity | Matriptase Antibody detects endogenous levels of total Matriptase |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | ST14 |
| Accession No. | Q9Y5Y6 |
| Alternate Names | Epithin; HAI; Matriptase; Membrane type serine protease 1; Membrane type serine protease; Membrane-type serine protease 1; MT SP1; MT-SP1; MTSP 1; MTSP1; Prostamin; PRSS 14; PRSS14; Serine protease 14; Serine protease TADG 15; Serine protease TADG-15; Serine protease TADG15; SNC 19; SNC19; ST 14; ST14; ST14_HUMAN; Suppression of tumorigenicity 14 (colon carcinoma matriptase epithin); Suppression of tumorigenicity 14 (colon carcinoma); Suppression of tumorigenicity 14; Suppressor of tumorigenicity 14 protein; Suppressor of tumorigenicity protein 14; TADG 15; TADG15; TMPRSS14; Tumor associated differentially expressed gene 15 protein; Tumor-associated differentially-expressed gene 15 protein; |
| Description | Degrades extracellular matrix. Proposed to play a role in breast cancer invasion and metastasis. Exhibits trypsin-like activity as defined by cleavage of synthetic substrates with Arg or Lys as the P1 site. Involved in the terminal differentiation of keratinocytes through prostasin (PRSS8) activation and filaggrin (FLG) processing. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 95kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |